clonazepam has been researched along with Multiple System Atrophy in 5 studies
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.
Multiple System Atrophy: A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We used ramelteon to treat two patients with secondary REM sleep behavior disorder (RBD) complications along with neurodegenerative diseases including multiple system atrophy and Parkinson's disease." | 7.79 | Use of ramelteon for the treatment of secondary REM sleep behavior disorder. ( Kawase, S; Nakashima, K; Nomura, T; Watanabe, Y, 2013) |
| "We used ramelteon to treat two patients with secondary REM sleep behavior disorder (RBD) complications along with neurodegenerative diseases including multiple system atrophy and Parkinson's disease." | 3.79 | Use of ramelteon for the treatment of secondary REM sleep behavior disorder. ( Kawase, S; Nakashima, K; Nomura, T; Watanabe, Y, 2013) |
| "Patients with rapid eye movement sleep behavior disorder are frequently prone to sleep-related injuries and should be treated to prevent injury with either melatonin 3-12 mg or clonazepam 0." | 2.55 | REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies. ( Boeve, AR; Boeve, BF; St Louis, EK, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| St Louis, EK | 1 |
| Boeve, AR | 1 |
| Boeve, BF | 1 |
| Nomura, T | 1 |
| Kawase, S | 1 |
| Watanabe, Y | 1 |
| Nakashima, K | 1 |
| Proukakis, C | 1 |
| Bonakis, A | 1 |
| Salman, AM | 1 |
| Kalfakis, N | 1 |
| Papageorgiou, SG | 1 |
| Cersosimo, MG | 1 |
| Koller, WC | 1 |
| Iranzo, A | 1 |
| Santamaría, J | 1 |
| Rye, DB | 1 |
| Valldeoriola, F | 1 |
| Martí, MJ | 1 |
| Muñoz, E | 1 |
| Vilaseca, I | 1 |
| Tolosa, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Center, Open Label Prospective Observational Pilot Study to Evaluate the Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)[NCT05922995] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-09-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for clonazepam and Multiple System Atrophy
| Article | Year |
|---|---|
REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies.
Topics: Central Nervous System Depressants; Clonazepam; GABA Modulators; Humans; Lewy Body Disease; Melatoni | 2017 |
4 other studies available for clonazepam and Multiple System Atrophy
| Article | Year |
|---|---|
Use of ramelteon for the treatment of secondary REM sleep behavior disorder.
Topics: Aged; Clonazepam; Female; Humans; Indenes; Male; Middle Aged; Multiple System Atrophy; Parkinson Dis | 2013 |
Exit, pursued by a bear.
Topics: Aged; Anticonvulsants; Clonazepam; Dreams; Humans; Male; Multiple System Atrophy | 2008 |
Movement disorders.
Topics: Adult; Aged; Anticonvulsants; Atrophy; Brain; Child; Clonazepam; Diagnosis, Differential; Female; Hu | 2003 |
Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD.
Topics: Age of Onset; Aged; Anticonvulsants; Brain; Clonazepam; Female; Humans; Logistic Models; Male; Middl | 2005 |